FDA grants Priority Review to Roche ’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Children | Food and Drug Administration (FDA) | Grants | Haemophilia | Hemophilia | Pharmaceuticals